A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

<h4>Introduction</h4>Radium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer. However, effects of combination radium-223 plus abiraterone or enzalutamide on survival a...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Stephanie I Kim, Andy H Szeto, Katherine P Morgan, Blaine Brower, Mary W Dunn, Amir H Khandani, Paul A Godley, Tracy L Rose, Ethan M Basch, Matthew I Milowsky, Young E Whang, Daniel J Crona
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/fee0788613ee46fca6169836edf043ce
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares